Viant Technology Sees FY21 Sales $205M-$210M
For the full year 2021, the Company is raising guidance and now expects:
Revenue in the range of $205 million to $210 million, which represents
Sight Sciences Q2 Sales $12.5M, Up 258% YoY
Generated second quarter 2021 total revenue of $12.5 million, an increase of 258% compared to the prior year period, including;
Surgical Glaucoma sales of $12.0 million, an increase
B of A Securities Initiates Coverage On Sight Sciences with Buy Rating, Announces Price Target of $45
B of A Securities analyst Bob Hopkins initiates coverage on Sight Sciences (NASDAQ:SGHT) with a Buy rating and announces Price Target of $45.
Citigroup Initiates Coverage On Sight Sciences with Buy Rating, Announces Price Target of $46
Citigroup analyst Joanne Wuensch initiates coverage on Sight Sciences (NASDAQ:SGHT) with a Buy rating and announces Price Target of $46.
Morgan Stanley Initiates Coverage On Sight Sciences with Equal-Weight Rating, Announces Price Target of $41
Morgan Stanley analyst Cecilia Furlong initiates coverage on Sight Sciences (NASDAQ:SGHT) with a Equal-Weight rating and announces Price Target of $41.
Piper Sandler Initiates Coverage On Sight Sciences with Overweight Rating, Announces Price Target of $44
Piper Sandler analyst Matt O'Brien initiates coverage on Sight Sciences (NASDAQ:SGHT) with a Overweight rating and announces Price Target of $44.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)